Bio-Rad Laboratories (BIO)
NYSE:BIO
Want to see BIO full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.75Last Year’s EPS
2.61Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Negative
The call presented a mix of operational and commercial progress (notably strong ddPCR instrument growth, strategic initiatives, solid liquidity and ongoing buybacks) but was dominated by near-term headwinds: meaningful currency‑neutral revenue declines, geopolitical disruption in the Middle East (an $11M Q1 impact and ongoing drag), margin pressure, weaker consumable pull‑through, and a material reported loss driven by the Sartorius mark‑to‑market adjustment. Management is pursuing cost and operational actions and adjusted full‑year guidance reflects a cautious near‑term outlook.Company Guidance
Reported Revenue Slightly Higher
Net sales of approximately $592 million in Q1 2026, a 1.1% increase on a reported basis versus $585 million in Q1 2025 (currency-neutral: -4.2% YoY).
Digital PCR Instrument Momentum
ddPCR instrument revenue increased 24% year-over-year; the new QX700 platform has >99% of digital PCR assays enabled ahead of plan, driving competitive wins, instrument growth and contributing to both revenue and margin expansion.
Diagnostics Reported Growth Outside Currency Impact
Clinical Diagnostics reported revenue of ~$364 million, up 1.9% on a reported basis versus prior year (currency-neutral: -4.1%), with quality systems and immunohematology franchises showing strength outside the Middle East disruption.
Balance Sheet and Capital Return Strength
Cash and short-term investments of $1.565 billion (vs. $1.541 billion at end of 2025); repurchased 176,000 shares in Q1 for ~$48 million and $542 million repurchased since Q1 2024 (2.1M shares).
Free Cash Flow Conversion and Ongoing Buybacks
Q1 free cash flow of $78 million (vs. $96 million prior year) and a free cash flow to non-GAAP net income conversion ratio of 153%; approximately $237 million available for additional buybacks under current authorization.
Operational and Strategic Progress
Initiatives include manufacturing select life science instruments in China for China to improve responsiveness, R&D portfolio reprioritization to focus investment, Stilla acquisition on track to be accretive by midyear, and a disciplined, targeted M&A focus on $100M–$500M revenue targets.
BIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $280.12 | $256.55 | -8.41% |
Feb 12, 2026 | $292.42 | $256.56 | -12.26% |
Oct 29, 2025 | $319.47 | $304.61 | -4.65% |
Jul 31, 2025 | $241.95 | $284.60 | +17.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIO EPS forecast?
BIO EPS forecast for the fiscal quarter 2026 (Q2) is 1.75.